Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. MRK
8. LVS
9. CSX
10. LRCX

Go back to Roth Positive on TG Therapeutics (TGTX) Following Q3 Results; Expects Strong ASH Showing

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update

November 10, 2014 4:15 PM EST

NEW YORK, Nov. 10, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq: TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for cancer and autoimmune diseases, today announced its results for the third quarter ended September 30, 2014 and recent company developments.

Financial Results for the Third Quarter 2014

At September 30, 2014 the Company had cash, cash equivalents, investment securities, and interest receivable of $67.3 million, which includes approximately $22.8 million of net proceeds from the utilization of the Company's at-the-market ("ATM") sales facility during the third quarter, as compared to $45.4 million at December... More